The prevalence of both chronic and acute kidney disease has risen worldwide, increasing the need for imaging procedures. However, their use is often restricted by contraindications to contrast agents, mainly due to the risks linked to gadolinium (Gd) in magnetic resonance image (MRI). Therefore, developing new biocompatible contrast agents is essential to reduce adverse effects and allow more patients to undergo these exams. In this context, new paramagnetic nanoparticles (PNPs) could be ideal for such applications.
Uchiyama et al. (Wed,) studied this question.